CDL-HM140-100μg / 询价
CDL-HM140-500μg / 询价
CDL-HM140-500μgx2 / 询价
Human CD40 Ligand/TNFSF5 Trimer Protein
Recombinant Human CD40 Ligand/TNFSF5 Trimer Protein is expressed from HEK293 with His tag and Flag tag at the N-Terminus.It contains Met113-Leu261 [Accession | P29965].
The protein has a predicted MW of 52.4 kDa, Due to glycosylation, the protein migrates to 55 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human CD40 Ligand Trimer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human CD40 Ligand Trimer is greater than 95% as determined by SEC-HPLC.
Immobilized Human CD40 Ligand Trimer, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Human CD40, hFc Tag with the EC50 of 101.8ng/ml determined by ELISA.
CD40 ligand or CD40L, also called CD154, is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily of molecules. It binds to CD40 (protein) on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In total CD40L has three binding partners: CD40, α5β1 integrin and αIIbβ3. CD154 acts as a costimulatory molecule and is particularly important on a subset of T cells called T follicular helper cells.
CD40L; CD40LG; CD154; TNFSF5; TNFSF5IMD3; CD40LIGM; gp39; HIGM1; T-BAM; TRAP; IGM; IMD3; CD40 Ligand
(1)Bjorck P , Filbert E , Zhang Y , et al. The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities[J]. Journal for Immunotherapy of Cancer, 2015, 3(S2):P198.
(2)Pound, J. D. Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells[J]. International Immunology, 1999, 11(1):11-20.
